Vol. 7 No. 2 (2006)

Published: 2006-06-15

Editorial

The breakthrough of public pharmaceutical expenditure in 2005

Mario Eandi

87-88
- PDF
- PDF

Review (Economic Analysis)

Telithromycin (Ketek®)in lower respiratory tract infections: economic aspects

Carlo Lazzaro

89-96
- PDF
Cost-effectiveness analysis of paclitaxel + carboplatin vs. alternative combinations in the treatment of non-small cell lung cancer

Mario Eandi

97-117
- PDF
Olanzapine versus typical neuroleptics for schizophrenia: evaluation of social and economic costs

Giorgio Mariani, Luca Guidi, Angelomarco Barioglio

119-124
- PDF

Original research

Resistenza all’uso degli ipoglicemizzanti orali nel trattamento del diabete tipo 2: uno studio multicentrico

Gianluca Falcitelli, Giuseppe Armentano, Corrado Pugliesi, Patrizio Tatti, Antonio Cimino

125-134
- PDF